Pharma finance boss steps down

Clinigen Group, the listed Burton pharmaceutical and services company, has appointed Nick Keher as group chief financial officer after Martin Abell resigned and leaves the business on 31 March 2019.

Abell will leave the business at the end of March. He has been with Clinigen since August 2015

Keher joins from Royal Bank of Canada (RBC) where he was a managing director and head of RBC’s European Healthcare equity research team. He has covered the European healthcare space for over eight years at both RBC and Investec.

Peter Allen, chairman of Clinigen, said: “On behalf of the Board and everyone at Clinigen, I would like to thank Martin for his substantial contribution over the last three and a half years. During which time Clinigen has undergone a period of rapid change and development including the acquisitions and integration of Idis, Link, Quantum and CSM, plus a number of products. We wish him every success for the future.”